The Medicines Company (MDCO) Expected to Announce Earnings of -$1.48 Per Share

Brokerages forecast that The Medicines Company (NASDAQ:MDCO) will post ($1.48) earnings per share for the current quarter, Zacks reports. Four analysts have issued estimates for The Medicines’ earnings, with estimates ranging from ($1.72) to ($1.11). The Medicines reported earnings per share of ($1.77) during the same quarter last year, which indicates a positive year-over-year growth rate of 16.4%. The company is scheduled to report its next quarterly earnings results on Tuesday, February 27th.

On average, analysts expect that The Medicines will report full year earnings of ($8.86) per share for the current year, with EPS estimates ranging from ($9.10) to ($8.48). For the next fiscal year, analysts forecast that the company will post earnings of ($3.95) per share, with EPS estimates ranging from ($4.02) to ($3.87). Zacks’ EPS averages are an average based on a survey of sell-side research firms that that provide coverage for The Medicines.

The Medicines (NASDAQ:MDCO) last posted its quarterly earnings data on Wednesday, October 25th. The company reported ($0.42) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.37) by $0.95. The Medicines had a negative net margin of 767.94% and a negative return on equity of 174.68%. The business had revenue of $16.87 million during the quarter, compared to the consensus estimate of $26.06 million. During the same period in the previous year, the firm posted ($0.64) earnings per share. The business’s revenue for the quarter was down 55.1% compared to the same quarter last year.

A number of research analysts recently issued reports on the stock. Oppenheimer set a $50.00 target price on shares of The Medicines and gave the company a “buy” rating in a research report on Monday, January 15th. ValuEngine upgraded shares of The Medicines from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Citigroup upgraded shares of The Medicines from a “neutral” rating to a “buy” rating and set a $40.00 target price for the company in a research report on Monday. Zacks Investment Research upgraded shares of The Medicines from a “sell” rating to a “buy” rating and set a $31.00 target price for the company in a research report on Tuesday, January 2nd. Finally, Guggenheim assumed coverage on shares of The Medicines in a research report on Monday, October 23rd. They set a “buy” rating and a $45.00 target price for the company. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. The Medicines presently has an average rating of “Buy” and a consensus target price of $52.11.

In other The Medicines news, CEO Clive Meanwell sold 136,250 shares of The Medicines stock in a transaction on Friday, December 15th. The shares were sold at an average price of $27.24, for a total value of $3,711,450.00. Following the completion of the transaction, the chief executive officer now owns 587,652 shares of the company’s stock, valued at $16,007,640.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Alexander J. Denner acquired 170,000 shares of the business’s stock in a transaction on Wednesday, November 29th. The stock was purchased at an average cost of $30.03 per share, with a total value of $5,105,100.00. Following the acquisition, the director now directly owns 6,663 shares of the company’s stock, valued at approximately $200,089.89. The disclosure for this purchase can be found here. Insiders own 8.22% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MDCO. Schwab Charles Investment Management Inc. increased its holdings in The Medicines by 3.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 302,528 shares of the company’s stock valued at $11,500,000 after buying an additional 8,900 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in The Medicines by 10.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock valued at $105,000 after buying an additional 264 shares in the last quarter. Riverhead Capital Management LLC increased its holdings in The Medicines by 74.0% in the second quarter. Riverhead Capital Management LLC now owns 6,960 shares of the company’s stock valued at $264,000 after buying an additional 2,960 shares in the last quarter. Amalgamated Bank increased its holdings in The Medicines by 7.0% in the second quarter. Amalgamated Bank now owns 9,575 shares of the company’s stock valued at $364,000 after buying an additional 629 shares in the last quarter. Finally, Stevens Capital Management LP purchased a new position in The Medicines in the second quarter valued at $284,000.

The Medicines (NASDAQ MDCO) traded up $1.66 during trading hours on Tuesday, hitting $30.47. 4,140,820 shares of the stock traded hands, compared to its average volume of 1,290,000. The Medicines has a 1-year low of $24.45 and a 1-year high of $55.95. The company has a quick ratio of 1.79, a current ratio of 2.31 and a debt-to-equity ratio of 3.42. The firm has a market capitalization of $2,220.00, a P/E ratio of -3.33 and a beta of 0.71.

TRADEMARK VIOLATION WARNING: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/23/the-medicines-company-mdco-expected-to-announce-earnings-of-1-48-per-share.html.

The Medicines Company Profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Get a free copy of the Zacks research report on The Medicines (MDCO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply